The addition of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to endocrine therapy in the treatment of patients with advanced hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer has significantly improved survival outcomes becoming the first-line standard of care therapy in this group of patients1–11. Here, CDK4 is linked to breast carcinoma.